( MENAFN - Investor Brand Network) Calidi Biotherapeutics (NYSE American: CLDI) , a leader in oncolytic virotherapy (OV) for cancer, will feature in a RedChip Small Stocks, Big MoneyTM interview on Bloomberg TV on Oct. 26 at 7 p.m.
ET. During the interview, Calidi's Chief Business Officer, Stephen Thesing, provides an update on Calidi's innovative approach, which uses engineered viruses to target and eliminate cancer cells. Calidi's proprietary cell-based technology enhances the potency and longevity of these viruses by protecting them from immune response, boosting treatment efficacy.
With IV-based and direct tumor administration methods, Calidi is advancing a new frontier in cancer treatment within the multi-billion-dollar oncology market. To view the full press release, visit: About Calidi Biotherapeutics Calidi Biotherapeutics specializes in proprietary technology that empowers the immune system to combat cancer. The company's novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors.
Calidi's clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi's preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially.
